XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals. The DIAGNODE-2 Trial.

Vaccine 103

Vaccine Vaccination Insulin Trials 103

XTalks

JANUARY 21, 2025

In a clinical trial, participants demonstrated a 98% success rate after six months post implantation, with arteries widened successfully and no stent fractures observed. In a trial with 100 patients , the device demonstrated no major complications, an average bleeding stop time of 2 minutes, with patients walking within approximately 2.5

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Delveinsight

AUGUST 25, 2021

Apart from these, Xarelto (for PAD) and Darzalex (for Amyloidosis and Refractory Multiple Myeloma) are in Phase III of clinical trials, while Tremfya (for Crohn’s Disease), Seltorexant (for insomnia), and Ciltacabtagene Autoleucei (BCMA CAR-T) (for multiple myeloma) are in Phase II of development. Imbruvica contributed USD 5.3 billion).

Vaccine 98

Vaccine Vaccination Drugs Sales 98